Breast Cancer Clinical Trial Using Lapatinib and Herceptin

- The folks at Dana-Farber Cancer Institute are studying the effects of Lapatinib; Herceptin on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start May 2007 and is expected to end circa December 2014.

Nancy Lin, MD
Overall Study Contact Info
StatusName Contact Phone
RecruitingNancy Lin, MDnlin@partners.org617-632-3800

This study is officially titled, "A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer."


Baylor College of Medicine

Houston, Texas - Active, not recruiting

Vanderbilt University

Nashville, Tennessee - Active, not recruiting

University of North Carolina

Chapel Hill, North Carolina - Active, not recruiting

Mayo Clinic

Rochester, Minnesota - Active, not recruiting

Dana-Farber at Faulkner Hospital

Boston, Massachusetts - Active, not recruiting

Beth Israel Deaconess Medical Center

Boston, Massachusetts - Recruiting

Dana-Farber Cancer Institute

Boston, Massachusetts - Recruiting

University of Chicago

Chicago, Illinois - Active, not recruiting

University fo Alabama at Birmingham

Birmingham, Alabama - Active, not recruiting

For more study details, please visit this link to record, which is the source of this webpage.